Skip to main content
Article thumbnail
Location of Repository

Mitosis Phase Enrichment with Identification of Mitotic Centromere-Associated Kinesin As a Therapeutic Target in Castration-Resistant Prostate Cancer

By Kanishka Sircar, Heng Huang, Limei Hu, Yuexin Liu, Jasreman Dhillon, David Cogdell, Armen Aprikian, Eleni Efstathiou, Nora Navone, Patricia Troncoso and Wei Zhang


The recently described transcriptomic switch to a mitosis program in castration-resistant prostate cancer (CRPC) suggests that mitotic proteins may be rationally targeted at this lethal stage of the disease. In this study, we showed upregulation of the mitosis-phase at the protein level in our cohort of 51 clinical CRPC cases and found centrosomal aberrations to also occur preferentially in CRPC compared with untreated, high Gleason–grade hormone-sensitive prostate cancer (P<0.0001). Expression profiling of chemotherapy-resistant CRPC samples (n = 25) was performed, and the results were compared with data from primary chemotherapy-naïve CRPC (n = 10) and hormone-sensitive prostate cancer cases (n = 108). Our results showed enrichment of mitosis-phase genes and pathways, with progression to both castration-resistant and chemotherapy-resistant disease. The mitotic centromere-associated kinesin (MCAK) was identified as a novel mitosis-phase target in prostate cancer that was overexpressed in multiple CRPC gene-expression datasets. We found concordant gene expression of MCAK between our parent and murine CRPC xenograft pairs and increased MCAK protein expression with clinical progression of prostate cancer to a castration-resistant disease stage. Knockdown of MCAK arrested the growth of prostate cancer cells suggesting its utility as a potential therapeutic target

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2006). A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
    2. (2008). A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
    3. (2002). Amplified centrosomes in breast cancer: a potential indicator of tumor aggressiveness.
    4. (2009). Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.
    5. (2006). Aurora B is enriched at merotelic attachment sites, where it regulates MCAK.
    6. (2009). Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.
    7. (2008). Cancer Statistics,
    8. (2000). Centrosome hyperamplification in head and neck squamous cell carcinoma: a potential phenotypic marker of tumor aggressiveness.
    9. (2004). Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer.
    10. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    11. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
    12. (2010). Docetaxelresistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition.
    13. (2008). Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity.
    14. (2011). Fatatis A
    15. (2010). Functional and spatial regulation of mitotic centromere-associated kinesin by cyclindependent kinase 1.
    16. (2009). Gamma tubulin: a promising indicator of recurrence in squamous cell carcinoma of the larynx.
    17. (2007). Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas.
    18. (2006). Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC3 human prostate cancer cell line.
    19. (2007). Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer.
    20. (2008). Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis.
    21. (2009). Kinesin motor proteins as targets for cancer therapy.
    22. (2005). Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.
    23. (2011). Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer. Eur Urol.
    24. (2010). NY-CO-58/ KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer.
    25. (2009). Overexpression of kinesins mediates docetaxel resistance in breast cancer cells.
    26. (2011). Overexpression of mitotic centromereassociated Kinesin stimulates microtubule detachment and confers resistance to paclitaxel.
    27. (2002). p53 Antiproliferative function is enhanced by aspartate substitution at threonine 18 and serine 20.
    28. (1995). Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo.
    29. (2003). Phosphorylation of serine 10 in histone H3, what for?
    30. (1999). Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotypebased screen.
    31. (2008). Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.